ACADIA Pharmaceuticals (ACAD) Competitors $20.95 +0.47 (+2.29%) Closing price 04:00 PM EasternExtended Trading$21.00 +0.05 (+0.26%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACAD vs. RGC, SMMT, BBIO, AXSM, and RDYShould you buy ACADIA Pharmaceuticals stock or one of its competitors? MarketBeat compares ACADIA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ACADIA Pharmaceuticals include Regencell Bioscience (RGC), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. ACAD vs. RGCACAD vs. SMMTACAD vs. BBIOACAD vs. AXSMACAD vs. RDYHow does ACADIA Pharmaceuticals compare to Regencell Bioscience?Regencell Bioscience (NASDAQ:RGC) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Which has more volatility and risk, RGC or ACAD? Regencell Bioscience has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Do analysts prefer RGC or ACAD? ACADIA Pharmaceuticals has a consensus target price of $31.63, indicating a potential upside of 50.95%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00ACADIA Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76 Which has preferable valuation and earnings, RGC or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Regencell Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegencell BioscienceN/AN/A-$3.58MN/AN/AACADIA Pharmaceuticals$1.07B3.35$391M$2.209.52 Does the media refer more to RGC or ACAD? In the previous week, Regencell Bioscience had 13 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 18 mentions for Regencell Bioscience and 5 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.21 beat Regencell Bioscience's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RGC or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 34.30% compared to Regencell Bioscience's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Regencell Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Regencell BioscienceN/A N/A N/A ACADIA Pharmaceuticals 34.30%9.61%7.07% Do institutionals and insiders believe in RGC or ACAD? 0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryACADIA Pharmaceuticals beats Regencell Bioscience on 12 of the 14 factors compared between the two stocks.How does ACADIA Pharmaceuticals compare to Summit Therapeutics?Summit Therapeutics (NASDAQ:SMMT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability. Does the media favor SMMT or ACAD? In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.32 beat ACADIA Pharmaceuticals' score of 0.21 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, SMMT or ACAD? Summit Therapeutics has a beta of -1.25, indicating that its share price is 225% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Is SMMT or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 34.30% compared to Summit Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -291.24% -243.07% ACADIA Pharmaceuticals 34.30%9.61%7.07% Do analysts rate SMMT or ACAD? Summit Therapeutics currently has a consensus target price of $27.58, indicating a potential upside of 54.18%. ACADIA Pharmaceuticals has a consensus target price of $31.63, indicating a potential upside of 50.95%. Given Summit Therapeutics' higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.50ACADIA Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76 Do institutionals & insiders hold more shares of SMMT or ACAD? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, SMMT or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit TherapeuticsN/AN/A-$1.08B-$1.60N/AACADIA Pharmaceuticals$1.07B3.35$391M$2.209.52 SummaryACADIA Pharmaceuticals beats Summit Therapeutics on 12 of the 15 factors compared between the two stocks.How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?BridgeBio Pharma (NASDAQ:BBIO) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Does the media favor BBIO or ACAD? In the previous week, BridgeBio Pharma had 5 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 10 mentions for BridgeBio Pharma and 5 mentions for ACADIA Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.65 beat ACADIA Pharmaceuticals' score of 0.21 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend BBIO or ACAD? BridgeBio Pharma presently has a consensus price target of $88.90, indicating a potential upside of 30.32%. ACADIA Pharmaceuticals has a consensus price target of $31.63, indicating a potential upside of 50.95%. Given ACADIA Pharmaceuticals' higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 1 Sell rating(s) 1 Hold rating(s) 23 Buy rating(s) 0 Strong Buy rating(s) 2.88ACADIA Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76 Do insiders & institutionals hold more shares of BBIO or ACAD? 99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, BBIO or ACAD? BridgeBio Pharma has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Is BBIO or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 34.30% compared to BridgeBio Pharma's net margin of -124.42%. ACADIA Pharmaceuticals' return on equity of 9.61% beat BridgeBio Pharma's return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-124.42% N/A -65.81% ACADIA Pharmaceuticals 34.30%9.61%7.07% Which has better valuation and earnings, BBIO or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$502.08M26.61-$724.93M-$3.74N/AACADIA Pharmaceuticals$1.07B3.35$391M$2.209.52 SummaryACADIA Pharmaceuticals beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?ACADIA Pharmaceuticals (NASDAQ:ACAD) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings. Do institutionals and insiders believe in ACAD or AXSM? 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is ACAD or AXSM more profitable? ACADIA Pharmaceuticals has a net margin of 34.30% compared to Axsome Therapeutics' net margin of -26.59%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals34.30% 9.61% 7.07% Axsome Therapeutics -26.59%-267.16%-28.53% Which has more volatility and risk, ACAD or AXSM? ACADIA Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Do analysts prefer ACAD or AXSM? ACADIA Pharmaceuticals presently has a consensus target price of $31.63, indicating a potential upside of 50.95%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 8.95%. Given ACADIA Pharmaceuticals' higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76Axsome Therapeutics 1 Sell rating(s) 1 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has higher earnings and valuation, ACAD or AXSM? ACADIA Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$1.07B3.35$391M$2.209.52Axsome Therapeutics$638.50M18.59-$183.17M-$3.73N/A Does the media refer more to ACAD or AXSM? In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Axsome Therapeutics. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 2 mentions for Axsome Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.21 beat Axsome Therapeutics' score of 0.02 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryACADIA Pharmaceuticals beats Axsome Therapeutics on 13 of the 16 factors compared between the two stocks.How does ACADIA Pharmaceuticals compare to Dr. Reddy's Laboratories?Dr. Reddy's Laboratories (NYSE:RDY) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Which has preferable earnings and valuation, RDY or ACAD? Dr. Reddy's Laboratories has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.58B3.17$484.20M$0.5823.47ACADIA Pharmaceuticals$1.07B3.35$391M$2.209.52 Is RDY or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 34.30% compared to Dr. Reddy's Laboratories' net margin of 12.90%. Dr. Reddy's Laboratories' return on equity of 12.16% beat ACADIA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories12.90% 12.16% 8.12% ACADIA Pharmaceuticals 34.30%9.61%7.07% Does the media refer more to RDY or ACAD? In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 4 mentions for Dr. Reddy's Laboratories. ACADIA Pharmaceuticals' average media sentiment score of 0.21 beat Dr. Reddy's Laboratories' score of 0.02 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of RDY or ACAD? 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, RDY or ACAD? Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Do analysts prefer RDY or ACAD? Dr. Reddy's Laboratories presently has a consensus target price of $16.90, suggesting a potential upside of 24.13%. ACADIA Pharmaceuticals has a consensus target price of $31.63, suggesting a potential upside of 50.95%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00ACADIA Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76 SummaryACADIA Pharmaceuticals beats Dr. Reddy's Laboratories on 12 of the 17 factors compared between the two stocks. Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAD vs. The Competition ExportMetricACADIA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.51B$3.27B$6.30B$12.12BDividend YieldN/A2.32%2.80%5.36%P/E Ratio9.5218.4221.0425.21Price / Sales3.35272.58530.1473.07Price / Cash23.09125.3543.1855.00Price / Book2.876.819.916.94Net Income$391M$24.18M$3.55B$335.25M7 Day Performance-5.55%-0.25%-0.30%-0.70%1 Month Performance-5.16%-4.58%-2.34%-0.90%1 Year Performance-3.41%55.65%30.89%29.67% ACADIA Pharmaceuticals Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACADACADIA Pharmaceuticals4.4138 of 5 stars$20.95+2.3%$31.63+51.0%-6.9%$3.51B$1.07B9.52510RGCRegencell Bioscience0.4189 of 5 stars$27.79-2.8%N/AN/A$14.13BN/AN/A10Trending NewsSMMTSummit Therapeutics2.7607 of 5 stars$16.02-5.0%$27.58+72.2%-34.0%$13.09BN/AN/A110Analyst DowngradeOptions VolumeBBIOBridgeBio Pharma3.6687 of 5 stars$65.32-1.2%$88.19+35.0%+95.9%$12.95B$502.08MN/A400Analyst ForecastInsider TradeAXSMAxsome Therapeutics2.3938 of 5 stars$227.40-0.1%$251.26+10.5%+109.3%$11.72B$638.50MN/A380 Related Companies and Tools Related Companies Regencell Bioscience Alternatives Summit Therapeutics Alternatives BridgeBio Pharma Alternatives Axsome Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Arrowhead Pharmaceuticals Alternatives Elanco Animal Health Alternatives Praxis Precision Medicines Alternatives Cytokinetics Alternatives Abivax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACAD) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
